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RNA interference (RNAi) is a biological process in which a double-
stranded RNA directs the silencing of target genes in a sequence-
specific manner. Exogenously delivered or endogenously encoded
double-stranded RNAs can enter the RNAi pathway and guide the
suppression of transgenes and cellular genes. This technique has
emerged as a powerful tool for reverse genetic studies aimed
toward the elucidation of gene function in numerous biological
models. Two approaches, the use of small interfering RNAs and
short hairpin RNAs (shRNAs), have been developed to permit the
application of RNAi technology in mammalian cells. Here we
describe the use of a shRNA-based live-cell microarray that allows
simple, low-cost, high-throughput screening of phenotypes caused
by the silencing of specific endogenous genes. This approach is a
variation of ‘‘reverse transfection’’ in which mammalian cells are
cultured on a microarray slide spotted with different shRNAs in a
transfection carrier. Individual cell clusters become transfected
with a defined shRNA that directs the inhibition of a particular
gene of interest, potentially producing a specific phenotype. We
have validated this approach by targeting genes involved in
cytokinesis and proteasome-mediated proteolysis.
RNA interference (RNAi) has emerged as one of the standardtechniques to study gene function in diverse experimental
systems. Introduction of double-stranded RNA (dsRNA) into a
cell decreases the level of the complementary mRNAs producing
a knockdown of the corresponding protein. The current model
of the RNAi mechanism proposes that the silencing ‘‘trigger’’ is
processed by Dicer into small RNAs of 21–22 nucleotides in
length. These become incorporated into an RNA-induced si-
lencing complex with endonuclease activity (RISC), which, in
turn, identifies and cleaves homologous mRNAs (1, 2).
Based on this approach, genomewide RNAi approaches have
been used successfully for phenotype-based screens in Caeno-
rhabditis elegans (3–5) and Drosophila melanogaster (6, 7). In
part, these successes derive from the availability of convenient
and inexpensive methods for producing and introducing dsRNA.
For example, it has previously been shown that RNAi can be
triggered by soaking C. elegans in a solution of dsRNA (8), or by
feeding worms with E. coli expressing gene-specific dsRNAs (9).
In Drosophila cells a soaking protocol is also available allowing
an easy method of introducing dsRNA (10).
Unfortunately, similarly straightforward approaches for trig-
gering silencing have not been described in mammals. Analysis
of multiples genes requires a ‘‘gene by gene’’ method, in which
individual transfections must be performed, making these stud-
ies expensive, tedious, and dependent on high-throughput ro-
botic systems. Cell microarrays represent a novel alternative to
classical approaches to phenotype-based assays in mammalian
cells.
Cell microarrays were first described by Ziauddin and Sabatini
(11), who demonstrated that cells grown on a glass substrate
could take up DNA–lipid complexes that had been deposited on
the slide before cells were plated. Cells essentially became
transfected in situ, with defined spots of transfected cells local-
ized over the printed DNAs. These studies demonstrated the use
of conventional DNA constructs for creating phenotypes based
on ectopic expression. Here we investigate the possibility of
similarly using cell microarrays for loss-of-function genetics. This
is accomplished by creating a microarray of living cells that have
been transfected in situ with either small interfering RNAs
(siRNAs) or with DNA constructs that direct the expression of
short hairpin RNAs (shRNAs). These are effective at initiating
a silencing response and in creating defined areas (spots) of cells
in which suppression of a targeted gene generates an expected
phenotype. Such arrays will find broad application to high-
throughput low-cost phenotype-based screens in mammalian
cells.
Materials and Methods
Microarray Printing and Reverse Transfection. Transfection mixes
containing DNA reporter vectors (500 ng) plus shRNAs (1 g)
or siRNAs (200 ng) were printed onto glass slides by using a
previously described ‘‘lipid method’’ (11) with some modifica-
tions. Briefly, nucleic acids were resuspended in 15 l of
DNA-condensation buffer (Buffer EC, Qiagen, Valencia, CA)
with a final concentration of 0.4 M sucrose. After two incubation
steps with the enhancer solution and the Effectene transfection
reagent (Qiagen), a 1 volume of 0.2% gelatin was remixed with
the solution to complete a transfection master mix of 45 l. Ten
microliters of this was aliquotted into a 384-well plate for
printing, and the remaining 35 l was stored at 4°C for later
assays. Samples were printed onto Corning GAPS II slides with
a PixSys 5500 Robotic Arrayer (Genomic Solutions, Ann Arbor,
MI). Pins transferred the ‘‘lipid–DNA’’ solution to the slide while
touching the surface of the slide for 500 ns. To ensure enough
printed area to contain several hundred cells, we printed in close
proximity nine spots forming a 3  3 square. After printing, the
nine spots fuse together forming a bigger single dot with a
diameter of 400–500 m. To prevent contamination after
printing, the slides were dried overnight at room temperature in
a tissue culture hood.
To perform the reverse transfection, one spotted array was
placed inside a 10-cm tissue culture dish and 15 ml of media
containing cells at a concentration of 1  106 per milliliter was
added into the dish taking care not to disturb the printed surface.
Cells were incubated for 60 h without media change before
analysis of the results (Fig. 1).
Reporter Assays. One hundred sixty dots containing a dual
reporter vector expressing GFPdsRed fluorescent proteins (gift
of Alla Karpova, Cold SpringHarbor Laboratory) and individual
shRNAs were printed. All shRNA were part of a library of U6
polymerase III promoter-driven hairpins (28). Four groups of
experiments with 40 dots (each) were printed: the first group
contained only dual reporter vector, the second group contained
the reporter vector plus an shRNA or siRNA against firefly
luciferase (Ff shRNA and Ff siRNA), the third group contained
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the reporter vector plus a shRNA or a siRNA against GFP that
has no effect in the expression level of the protein (GFP
shRNA-1 and GFP siRNA-1), and the last group contained the
reporter vector plus a shRNA that reduces by 90% the GFP
signal when tested in culture plates (GFP shRNA-2 and GFP
siRNA-2).
Several cell lines were tested for transfection, NIH 3T3,
IMR90E1A, HeLa, and HEK 293T. To test the stability of the
printed array, we repeated the assay at different time points after
printing, day 0, 1 week, 2 weeks, 4 weeks, and 2 months. For
testing the stability of the transfection master mix, we stored the
solution at 4°C and then printed new slides and assayed them at
the time points described above.
Proteasome-Mediated Proteolysis Assays. Thirty shRNAs targeting
different proteasome subunits were printed in triplicate. Every
dot harbored an shRNA-expression vector, a plasmid expressing
dsRed (dsRed N-1, Clontech), and a vector encoding a protea-
some fluorescent reporter (ZsProSensor, Clontech). This re-
porter encodes a fusion protein that has been engineered to show
varying levels of expression depending on the status of the
proteasome pathway. Every transfection master mix contained
400 ng of dsRed vector, 100 ng of ZsProSensor, and 1 g of
shRNA plasmid. Twenty micrograms of total protein lysates was
used for Western blot analysis. Rabbit anti-PSMC-6 subunit of
the proteasome (Affinity, Biomol, Plymouth Meeting, PA),
rabbit anti-ubiquitin (StressGen Biotechnologies, Victoria, Can-
ada), and mouse anti--actin (United States Biological, Swamp-
scott, MA) antibodies were also used in these studies.
Cytokinesis Defect Assays. Eight shRNAs targeting the motor
protein Eg5 were printed (10 replicas each) together with a
vector encoding an -tubulin-GFP fusion protein (GFP-tubulin,
Clontech). Every transfection mix contained 1 g of Eg5 hairpin
and 500 ng of the fluorescent fusion protein expression plasmids.
For immunofluorescence studies, we printed a replica slide
where the transfection mix contained 500 ng of the dsRed
reporter instead of the GFP-tubulin. Cells were stained by using
standard methods with small variations. After incubation of the
slides for 60 h the cells were fixed with paraformaldehyde for 10
min, washed very gently, and permeabilized with 1% Triton
X-100 in PBS for 15 min on ice. Only one 15-min wash was
performed to avoid washing away the cells. Mouse anti--tubulin
(Sigma) was used in this study. Hoechst dye was included in the
last wash to visualize the chromosomes.
Ninety-Six-Well Plate Analyses. All RNAi microarray results were
validated by using cells transfected in 96-well tissue culture
plates. Cells were transfected with LT-1 (Mirus, Madison, WI)
according to the manufacturer’s instructions at 50–70% conflu-
ence. The plasmids containing appropriate constructs were
cotransfected, keeping the same ratios used in the arrayed slides
but with a total mass of 100 ng of DNA for each transfected well.
Again, results were analyzed after 60 h of incubation.
Results
Targeting Reporter Genes in Situ by Using siRNAs. Given previous
successes in ectopically expressing genes by reverse transfection
(11), we hoped that similar approaches could be coupled with the
use of RNAi to produce knockdown phenotypes. Therefore, we
began by testing the ability of siRNAs to be deposited on a
microarray as lipid–RNA complexes and to cause sequence-
specific silencing in cells grown on the arrays. We began by
testing the ability of siRNAs to silence a co-delivered, ectopic
marker. For convenience, we used GFP to enable both trans-
fection and silencing to be scored by visual inspection. Because
GFP was the siRNA target, we also included a plasmid that
directs the expression of a second fluorescent protein (dsRed) to
allow us to verify that siRNAs specifically silenced GFP expres-
sion rather than simply interfered with transfection.
Several siRNAs homologous to the GFP coding sequence
were mixed with plasmids encoding GFP and dsRed. Nucleic
acids were combined with a variety of lipid reagents [LT-1 or
TKO (Mirus) and Effectene (Qiagen)], and the lipid–nucleic
acid complexes were spotted onto glass slides. We found that
Qiagen reagent performed best, giving optimal transfection of
both DNA and RNA in this experiment. GFP siRNAs that had
been previously identified as an efficient suppressor of the
expression of the fluorescent protein in standard transfections
(GFP siRNA-2) also showed potency on the spotted array.
Ineffective siRNAs (GFP siRNA-1) or unrelated siRNAs (Ff
siRNA) did not produce any effect on GFP expression levels
either in standard transfections or on microarray slides (Fig. 2A).
Targeting Reporter Genes in Situ by Using shRNAs. The aforemen-
tioned studies demonstrated that an RNAi response could be
initiated by in situ transfection of siRNAs on glass-slide microar-
rays. As stated above, RNAi can also be initiated in mammalian
cells by transfection of DNA expression constructs that direct the
synthesis of shRNA sequences. We therefore tested the possi-
bility that a slide printed with a transfection mix containing an
shRNA-expression construct that targets a specific mRNA could
initiate a specific silencing response in in situ transfected cell
clusters. As a first step, we again tested our ability to down-
regulate the expression of GFP. Spots were printed as described
above. In every cell cluster, the GFP level reported specific
RNAi-mediated suppression and the dsRed level again acted as
a transfection control.
As expected, none of the spots containing the reporter vector
alone, the reporter plus a control shRNA, targeting firefly
luciferase, or the reporter plus GFP shRNA-1, an ineffective
shRNA, showed any reduction in the expression of GFP. In
contrast, all spots harboring the GFP shRNA-2, an active
shRNA, presented a strong attenuation of the GFP signal while
maintaining unaltered levels of dsRed protein (Fig. 2B). It is
worth noting that all suppressed samples showed a similar degree
of attenuation of GFP and a very similar percentage of trans-
fected cells, revealing a high degree of consistency from spot to
spot.
We next asked whether the in situ RNAi procedure could be
applied broadly by examining the response of a number of
different cell lines in an arrayed format. These included trans-
formed and nontransformed cells lines, fibroblasts and epithelial
cells, and lines from mouse and human. Of those tested, HEK
Fig. 1. Outline of the protocol used to perform reverse transfection on a
glass slide. Transfectionmixes containinggelatinwere spottedonGAPS II glass
slides with a PixSys 5500 Robotic Arrayer to form a 3  3 square. Dried slides
were put inside a 10-cm tissue culture dish, and mediumwith cells was added
to the dish. After incubation, groups of transfected cells could be detected
inside the spotted transfection mixes.






293T cells showed the highest efficiency. IMR90E1A, NIH 3T3,
and HeLa cells showed lower efficiency (20–50%) than 293T
(data not shown). Our results indicate that by varying the lipid
and nucleic acid content of the spot, many different cell lines can
be used. However, for convenience, we performed the remain-
der of our assays with HEK 293T.
We also examined the stability of slides spotted with lipid
shRNA mixtures and with lipidsiRNA mixtures. We printed
replica slides and compared both transfection efficiency and
silencing efficiency at various time points. We did not observe
any reduction in the performance of the shRNA arrays after 1
week, 1 month, or up to 2 months of storage at 4°C. In contrast,
siRNA printed slides showed more variability, and unclear
results were obtained after 2 weeks of storage.
An in Situ Assay for Defects in Proteosome Function. The need to
locate transfected cells to score phenotypes on the array led to the
consideration of phenotypic assays that depended on the expression
of a fluorescent, exogenous reporter gene. The basic idea, a
variation of the validation experiments described above, was to
include in the transfection mix a plasmid harboring a fluorescent
reporter that is differentially expressed (at higher or lower level) in
cells in which RNAi has been used to alter the function of a specific
pathway. To test this approach, we focused on protein half-life as a
determinant of steady-state expression levels. A variety of motifs
have been found to confer a short lifetime on cellular proteins.
So-called PEST sequences are rich in the amino acids Pro (P), Asp,
Glu (E), Ser (S), and Thr (T), which occur in internal positions in
the sequence. Proteins containing PEST sequence elements are
rapidly targeted to the 26S proteasome for degradation (12).
The mouse ornithine decarboxylase (MODC) has an ex-
tremely short half-life (13). MODC degradation is mediated by
an internal domain, called MODC-d410, that contains several
PEST motifs. This functional motif is transferable, decreasing
greatly the stability of proteins to which it is fused (14, 15). This
property has been exploited to create commercially available
reporter systems in which MODC-d410, appended to a fluores-
cent protein, creates a fusion that can indicate the integrity of the
proteosome in living cells.
We chose to analyze the expression level of a commercially
available reporter consisting of a green f luorescent protein
(ZsGreen) tagged on the carboxyl-terminus with the MODC-
d410 domain (ZsProSensor, Clontech). We recently screened
a library of 7,000 individual shRNAs for the ability to antag-
onize proteosome function in a 96-well plate format (28).
Roughly one-quarter of primary positives targeted proteosome
subunits. Putative positives from that screen were used on
microarrays to validate the in situ approach and to compare the
sensitivity of array-based assays to those carried out in 96-well
plates. Based on these previous studies, thirty different hair-
pins targeting proteasome subunits were deposited, each in
individual spots, together with the destabilized green reporter
and a dsRed vector. As in previously described experiments,
dsRed served as transfection control.
After 24 h of incubation we observed higher levels of ZsGreen
protein in several dots containing proteasome shRNAs com-
pared to control shRNAs, whereas no changes were observed in
the intensity of the red fluorescent protein. During the following
48 h the green fluorescent signal gradually increased in these
positive spots, achieving maximum intensity after 60–72 h. We
identified clear differences in the accumulation level of the
reporter in spots containing proteasome shRNAs compared with
nonproteasome hairpins. Interestingly, the most intense signals
were revealed from spots containing shRNAs that target sub-
units of the 19S base (Fig. 3A).
To confirm that the increased expression of the reporter was
associated with alterations in proteasome function, we verified
that cells transfected with a hairpin against the ATPase subunit
6 indeed showed a specific reduction of the targeted protein. As
expected, Western blot analysis of transiently transfected 293T
Fig. 2. The GFP reporter is specifically suppressed by RNAi in 293T cells
incubated for 48 hon aprinted glass slide. (A) Printed spots contained a vector
expressing GFP and dsRed reporters and individual siRNAs targeting different
sequences (as indicated): no siRNA (—), Ff, siRNA-1 (GFP-1), and siRNA-2
(GFP-2). (B) Printed spots contained a vector expressingGFP and dsRed report-
ers and individual shRNA expression plasmids targeting different sequences
(as indicated): no hairpin (-), Ff, hairpin 1 (GFP-1), and hairpin 2 (GFP-2).
Control spots harbored siRNAoran shRNA-expression vector against Ff,GFP-1,
or no added RNAi inducer (mock).
Fig. 3. (A) Different levels of ZsGreen protein accumulation detected in the
RNAi microarray. (B) HEK 293T were incubated with individual hairpins tar-
geting theexpressionofdifferent proteasome subunits. AWesternblot shows
specific inhibition of ATPase-6 shRNA. Firefly shRNA was used as control. (C)
Anti-ubiquitinWestern blot showing accumulation of polyubiquitinated pro-
teins in treated cells.
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cells with the ATPase-6 shRNA-1 showed a specific reduction in
the level of the targeted protein (Fig. 3B).
It has been shown previously that in cells in which the normal
function of the proteasome is blocked, there is an accumulation
of polyubiquitinated proteins (16, 17). To validate further the
antagonism of proteosome function by RNAi, we examined the
level of polyubiquitinated proteins. Indeed, analysis of bulk
ubiquitinated proteins by Western blotting with a ubiquitin
antibody revealed an increase in these normally unstable species
in cells treated with proteasome shRNAs compared with con-
trols (Fig. 3C).
A Screen for Alterations in Cell Cycle Control: Cytokinesis Defects.The
aforementioned screen was amenable to the use of microarray
scanners to score positives by their ratio of fluorescent signals.
To examine the suitability of this approach for other types of
screens, we performed a live-cell microarray assay to identify
cytokinesis defects induced by RNAi. As a reconstruction ex-
periment, we knocked down the mitotic motor protein Eg5,
because cytokinesis defects in cells where Eg5 function is
inhibited are well established (18, 19).
The mitotic spindle, which consists of a dynamic array of
microtubules and associated proteins, is responsible for segre-
gation of chromosomes during mitosis. Studies using immu-
nodepletion (20, 21) of the motor kinesin Eg5 or with the specific
inhibitor monastrol (18) have revealed that inhibition of the
normal function of this protein causes a defect in spindle
formation. Initially, a defect in centrosome separation causes the
assembly of monopolar spindles, and eventually, aberrant struc-
tures form that look like ‘‘rosettes’’ of microtubules with DNA
at the periphery.
Based on the expectation of this typical morphology, we printed
DNA–lipid complexes containing individual shRNAs targetingEg5
on microarray slides. Transfection mixes also contained a plasmid
encoding an -tubulin GFP fusion protein. In this array, the GFP
fusion protein identifies the cells that have been transfected and
allows visualization of microtubules. Additionally, when the mi-
croarraywas scored,Hoechst 33342was added to themedia to allow
visualization of chromosomes. The analysis of the array revealed
two hairpins that produced cells displaying the characteristic ‘‘ro-
sette’’ pattern (Fig. 4). We did not observe this phenotype in any of
the spots containing control shRNAs. This phenotype was also
observedwhen shRNAs targeting Eg5were tested in a 96-well plate
format and was similar to the phenotype obtained after Eg5
inhibition by monastrol (data not shown).
The use of vectors harboring reporters or fusion proteins is a very
convenient approach to identify abnormal phenotypes by in situ
transfection. However, appropriate reagents will not be easily
available for all interesting phenotypes. For this reason, we asked
whether it was possible to identify Eg5 suppression phenotypes by
the conventional technique of immunofluorescence (IF). A replica
of the Eg5 glass slide, in which the -tubulin fluorescence reporter
was replaced by dsRed, was stainedwith a standard IF protocol.We
find that we could easily identify cytokinesis defects produced by
the same shRNAs identified with the -tubulin GFP protein by
using this methodology (data not shown).
Discussion
Genomewide analyses of loss-of-function phenotypes in mammals,
similar to classic genetic studies in yeast, were very difficult, if not
impossible, only a few years ago. However, over the last several
years RNAi has emerged as a powerful approach for manipulating
gene expression in mammalian cells, opening the door to the
execution of such screens. High-throughput RNAi analyses have
previously been used to study gene function inD. melanogaster and
C. elegans. For example, essential genes (22), G protein-coupled
receptors (GPCRs) (23), fat regulatory genes (24), and genes that
regulate lifespan (25) have been functionally analyzed by this
approach. Unfortunately, similar studies in mammals still represent
a technological challenge. In part, limitations occur because of the
cost of the RNA species themselves and the cost of introducing
these species (siRNA and shRNA) into mammalian cells. Addi-
tionally, the use of a large-scale analysis in any system is limited by
the screening methodology.
Here we validate the use of a cost-effective high-throughput
procedure for RNAi-based screens in mammalian cells. This
procedure is based on methodologies developed by Sabatini and
colleagues (11) for creating high copy suppression phenotypes by
‘‘reverse transfection.’’ This allows for the cost-effective use of
materials, both the nucleic acids themselves and tissue culture
reagents. We estimate that between 100 and 500 reverse trans-
fections can be done with the materials required for a single
transfection in a well of a 96-well plate. Additionally, thousands
of samples can be printed in parallel on a glass-slide microarray,
reducing the time and cost associated with maintaining cultures
and analyzing phenotypic outputs. Finally, as previously de-
scribed, printed slides can be stored for several months without
losing potency (11).
By comparing results obtained by initiating RNAi in situ on
microarrays to screens conducted in 96-well plates, we find that the
arrays compare favorably to standard methods for both sensitivity
and specificity. In agreement with our data, two recent papers have
reported that RNAi could be initiated on printed slides to inhibit
the expression of a co-delivered marker gene (26, 27). Our study
extends these results by showing that a similar procedure can be
used to silence endogenous genes to create RNAi-induced pheno-
types relevant to two independent biological pathways.
Firstly, we designed an assay to study proteosome-mediated
degradation. As predicted, when subunits of the 26S proteasome
were targeted by shRNAs, we could clearly identify accumula-
tion of an engineered protein that is normally degraded by the
proteasome pathway. We showed that proteolytic defects were
due to specific suppression of the targeted 26S subunits and
demonstrated that cellular levels of the natural proteasome
substrates (ubiquitinated proteins) were affected in the same way
as the fluorescent reporter. In a second study, we analyzed the
effect produced by loss of kinesin Eg5 as model for cytokinesis
defects. After targeting with Eg5 shRNAs, we could reproduce
the expected aberrant spindle morphology in a printed slide
format, while no changes were observed in control spots.
Here, we demonstrate the feasibility of using printed arrays of
siRNAs and shRNAs for highly parallel phenotype analysis in
living cells. This approach is f lexible and provides low-cost
alternatives to similar screens carried out in multiwell plate
formats. As large libraries of shRNAs become widely available
Fig. 4. Cytokinesis defects inducedbyEg5 shRNAs. (Upper) Sampleof normal
mitotic metaphase detected in a dot containing firefly (control) shRNA.
(Lower) Two typical ‘‘rosette’’ phenotype found in a printed spot containing
the shRNA-7 against the motor protein Eg5.






(28, 29), the techniques described herein will become a powerful
approach to genetic analysis in mammalian cells.
We thank JimDuffy for help with preparation of the figures andMichelle
Carmell, Ahmet Denli, Liz Murchinson, Lin He, and William M. Keyes
for critical reading of the manuscript. J.M.S. is supported by a postdoc-
toral fellowship from the U.S. Army Prostate Cancer Research Program,
and G.J.H. is supported by an Innovator Award from the U.S. Army
Breast Cancer Research Program. This work was supported in part by
grants from the National Institutes of Health.
1. Zamore, P. D. (2001) Nat. Struct. Biol. 8, 746–750.
2. Hannon, G. (2002) Nature 418, 244–251.
3. Maeda, I., Kohara, Y., Yamamoto, M. & Sugimoto, A. (2001) Curr. Biol. 11,
171–176.
4. Ashrafi, K., Chang, F. Y., Watts, J. L., Fraser, A. G., Kamath, R. S., Ahringer,
J. & Ruvkun, G. (2003) Nature 421, 268–272.
5. Pothof, J., vanHaaften, G., Thijssen, K., Kamath, R. S., Fraser, A. G., Ahringer,
J., Plasterk, R. H. & Tijsterman, M. (2003) Genes Dev. 17, 443–448.
6. Somma, M. P., Fasulo, B., Cenci, G., Cundari, E. & Gatti, M. (2002)Mol. Biol.
Cell. 13, 2448–2460.
7. Kiger, A., Baum, B., Jones, S., Jones, M., Coulson, A., Echeverri, C. &
Perrimon, N. (2003) J. Biol. 2, 27.
8. Tabara, H., Grishok, A. M. &. Mello, C. C. (1998) Science 282, 430–431.
9. Timmons, L. & Fire, A. (1998) Nature 395, 854.
10. Clemens, J. C., Worby, C. A., Simonson-Leff, N., Muda, M., Maehama, T.,
Hemmings, B. A. & Dixon, J. E. (2000) Proc. Natl. Acad. Sci. USA 97, 6499–6503.
11. Ziauddin, J. & Sabatini, D. M. (2001) Nature 411, 107–110.
12. Rechsteiner, M. & Rogers, S. W. (1996) Trends Biochem. Sci. 21, 267–271.
13. Murakami, Y., Matsufuji, S., Kameji, T., Hayashi, S., Igarashi, K., Tamura, T.,
Tanaka, K. & Ichihara, A. (1992) Nature 360, 97–99.
14. Olmo, M. T., Rodriguez-Agudo, D., Medina, M. A. & Sanchez-Jimenez, F.
(1999) Biochem. Biophys. Res. Commun. 257, 269–272.
15. Verma, R. & Deshaies, R. J. (2000) Cell 101, 341–344.
16. Wojcik, C. & DeMartino, G. N. (2002) J. Biol. Chem. 277, 6188–6197.
17. Bochtler, M., Ditzel, L., Groll, M., Hartmann, C. & Huber, R. (1999) Annu.
Rev. Biophys. Biomol. Struct. 28, 295–317.
18. Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L. &
Mitchison, T. J. (1999) Science 286, 971–974.
19. Goshima, G. & Vale, R. D. (2003) Cell Biol. 162, 1003–1016.
20. Sawin, K. E., LeGuellec, K., Philippe, M. & Mitchison, T. J. (1992) Nature 359,
540–543.
21. Blangy, A., Lane, H. A., d’Herin, P., Harper, M., Kress, M. &Nigg, E. A. (1995)
Cell 83, 1159–1169.
22. Maeda, I., Kohara, Y., Yamamoto, M. & Sugimoto, A. (2001) Curr. Biol. 11,
171–176.
23. Keating, C. D., Kriek, N., Daniels, M., Ashcroft, N. R., Hopper, N. A., Siney,
E. J., Holden-Dye, L. & Burke, J. F. (2003) Curr. Biol. 13, 1715–1720.
24. Ashrafi, K., Chang, F. Y., Watts, J. L., Fraser, A. G., Kamath, R. S., Ahringer,
J. & Ruvkun, G. (2003) Nature 421, 268–272.
25. Lee, S. S., Lee, R. Y., Fraser, A. G., Kamath, R. S., Ahringer, J. & Ruvkun, G.
(2003) Nat. Genet. 33, 40–48.
26. Mousses, S., Caplen. N. J., Cornelison, R., Weaver, D., Basik, M., Hautaniemi,
S., Elkahloun, A. G., Lotufo, R. A., Choudary, A., Dougherty, E. R., et al.
(2003) Genome Res. 13, 2341–2347.
27. Kumar, R., Conklin, D. S. & Mittal, V. (2003) Genome Res. 13, 2333–2340.
28. Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S.
Balija, V., O’Shaughnessy, A., Gnoj, L., Scobie, K., et al. (2004) Nature 428,
427–431.
29. Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A.,
Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B.,
et al. (2004) Nature 428, 431–437.
6552  www.pnas.orgcgidoi10.1073pnas.0400165101 Silva et al.
